Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 1.09 Billion |
| Market Size (2030) | USD 1.55 Billion |
| Growth Rate (2025 - 2030) | 7.84% CAGR |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Australia Veterinary Healthcare Market Analysis by Mordor Intelligence
The Australia veterinary healthcare market stands at USD 1.09 billion in 2025 and is forecast to reach USD 1.55 billion by 2030, translating to a 7.84% CAGR over the period. The current market size reflects sustained expenditure growth on animal health products and services, while the projected CAGR highlights the resilience of the Australia veterinary healthcare market despite workforce and cost pressures. Key momentum builders include a triple-digit surge in annual pet spending, rising biosecurity outlays, and expanding livestock exports that collectively widen the revenue base for therapeutics, diagnostics, and ancillary services. Consolidation among corporate practice groups is reshaping competitive intensity, and technology adoption—most notably AI-enabled diagnostics—is shortening decision times and creating new service lines. Government funding for novel vaccines, alongside insurance penetration gains, underpins both preventive care adoption and market opportunity recognition across urban and rural settings.
Key Report Takeaways
- By product, therapeutics led with 61.34% revenue share in 2024; diagnostics are forecast to expand at a 7.45% CAGR through 2030.
- By animal type, dogs and cats held 44.78% of the Australia veterinary healthcare market share in 2024, whereas poultry is projected to grow at an 8.45% CAGR to 2030.
- By route of administration, parenteral formulations accounted for 48.53% of the Australia veterinary healthcare market size in 2024 and oral products are expected to post a 7.65% CAGR through 2030.
- By end user, hospitals and clinics secured 53.76% revenue share in 2024, while point-of-care testing settings are advancing at an 8.43% CAGR to 2030.
Australia Veterinary Healthcare Market Trends and Insights
Driver Impact Analysis
| Driver | % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising animal health expenditure | +2.1% | National (urban focus) | Long term (≥ 4 years) |
| Livestock export industry growth | +1.8% | Queensland & Western Australia | Medium term (2-4 years) |
| Increasing pet ownership & urbanization | +1.6% | Metropolitan areas | Long term (≥ 4 years) |
| Veterinary technology advancements | +1.4% | Major cities | Medium term (2-4 years) |
| Government biosecurity initiatives | +0.9% | Agricultural regions | Short term (≤ 2 years) |
| Pet insurance coverage expansion | +0.7% | Urban centers | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Animal Health Expenditure
Annual pet outlays have soared to USD 33 billion, nearly triple 2019 levels, confirming a deepening human-animal bond that supports premium medical, surgical, and preventive services. Owners increasingly authorize procedures that cost over USD 10,000, prompting clinic investment in advanced equipment and specialty staffing. This spending reliability encourages capital allocation toward imaging suites, endoscopy units, and regenerative therapies. Parallel growth in insurance enrollment improves affordability for high-ticket interventions and balances clinic revenue cycles. The Australia veterinary healthcare market therefore benefits from recurrent, diversified spend streams that raise baseline demand.
Growth In Livestock Export Industry
Livestock exports generate USD 67 billion per year and sustain 428,000 jobs, compelling producers to engage veterinarians for continuous surveillance, certification, and emergency preparedness. Fear of foot-and-mouth disease, with modeled losses of USD 80 billion, elevates the value placed on vaccination and diagnostic regimes. Breakthroughs in mRNA vaccine research position Australia as both a user and supplier of novel biologics, adding an exportable pharmaceutical dimension to the Australia veterinary healthcare market.
Increasing Pet Ownership & Urbanization
Urban professionals delay parenthood yet adopt pets at higher rates, driving concentrated spend in Sydney, Melbourne, and Brisbane. Apartment living brings behavioral and lifestyle disorders that necessitate nutritional counseling and specialized medical care. Specialty centers offering oncology and cardiology flourish in these catchments, where owners equate animal welfare with human standards[1]American Veterinary Medical Association, “AI solutions in veterinary diagnostics,” avma.org. The Australia veterinary healthcare market thus gains depth through niche service proliferation.
Advancements In Veterinary Technologies
Thirty percent of veterinarians have integrated AI-powered image analysis, cutting diagnostic turnaround from days to hours and enhancing clinical throughput. Point-of-care (POC) devices now return hematology panels during consultations, enabling same-visit therapies. Telemedicine extends specialist expertise to remote communities, while digital practice systems trim administration overhead. Collectively, technology raises service capacity and widens reach, accelerating revenue within the Australia veterinary healthcare market.
Restraints Impact Analysis
| Restraints Impact Analysis | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High veterinary service costs | -1.2% | Rural communities | Medium term (2-4 years) |
| Stringent regulatory approval processes | -0.9% | Nationwide | Medium term (2-4 years) |
| Skilled veterinary workforce shortage | -0.8% | National (rural acute) | Long term (≥ 4 years) |
| Counterfeit animal medicines proliferation | -0.6% | Selected import channels | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
High Cost of Veterinary Services
Clinic prices climb more than 8% per year, driven by equipment amortization, compliance overhead, and staff retention costs. Budget-constrained owners delay care, weakening preventive uptake and shifting volume toward emergency interventions. Overdiagnosis narratives in mainstream media erode trust and intensify price sensitivity[2]Sydney Morning Herald, “Pet owners query over-treatment trend,” smh.com.au. This pressure caps upside in some localities of the Australia veterinary healthcare market even as aggregate spend rises.
Shortage Of Skilled Veterinary Workforce
Rural practices struggle to recruit and retain clinicians, with attrition fueled by workload stress and limited career pathways. Veterinary nurse burnout affects 42% of the support labor pool, straining patient throughput and service quality. Training capacity expansions will not offset gaps until after 2027, prolonging supply-demand imbalances in the Australia veterinary healthcare market.
Segment Analysis
By Product: Therapeutics Lead While Diagnostics Accelerate
Therapeutics contributed 61.34% to 2024 revenue as vaccines, parasiticides, and anti-infectives formed the backbone of clinical interventions. Government funding for avian influenza preparedness and world-first livestock mRNA projects boosts vaccine demand. Parasiticide uptake remains robust due to outdoor pet lifestyles, and antimicrobial stewardship programs guide prudent anti-infective use. In contrast, diagnostics posted only a modest base in 2024 yet display a 7.45% CAGR through 2030, signaling a pivot toward early disease recognition and wellness screening. Immunoassay kits dominate the Australia veterinary healthcare market size for diagnostics, and AI image analysis platforms create subscription revenue streams for early adopters. Consequently, therapeutics will maintain volume leadership, but diagnostics will shape margin expansion strategies for providers across the Australia veterinary healthcare market.
Diagnostics growth also stems from practice conversion to POC devices that allow same-day decision-making and client reassurance. Molecular assays detecting zoonotic agents fit national biosecurity objectives and attract cost-sharing grants. Bundled wellness plans incorporating annual screening lock in client loyalty and stabilize cash flow. Together, these dynamics illustrate how preventive paradigms are remolding product mix in the Australia veterinary healthcare market.
Note: Segment shares of all individual segments available upon report purchase
Get Detailed Market Forecasts at the Most Granular Levels
Download PDF
By Animal Type: Companion Animals Dominate, Poultry Surges
Dogs and cats secured a 44.78% share in 2024, benefiting from urban humanization trends and growing insurance coverage that finances complex care regimens. Specialty services such as oncology and orthopedics push average transaction values higher. Nonetheless, poultry registers the quickest growth at an 8.45% CAGR, tied to export expansion and strict international health standards. Avian producers require continuous surveillance, vaccination, and certification, channeling revenue toward biologics and diagnostics. The Australia veterinary healthcare market share for livestock overall rises as producers preempt economic shock from disease outbreaks.
Equine medicine retains a high-value niche linked to racing, while aquaculture opens incremental upside through vaccine innovation targeting Iridoviridae. Sheep and goats remain underserved, offering white-space potential for practices developing small-ruminant expertise. Broadly, companion animal volume sustains core demand, and poultry ensures incremental lift, maintaining balance in the Australia veterinary healthcare market.
By Route Of Administration: Parenteral Leads, Oral Gains Momentum
Parenteral products accounted for 48.53% of revenue in 2024, reflecting clinician preference for rapid-onset injectables in critical and livestock scenarios[3]Australian Pesticides and Veterinary Medicines Authority, “Antimicrobial stewardship guidelines,” apvma.gov.au. Emergency care, herd vaccinations, and depot formulations anchor this dominance. However, oral delivery posts a 7.65% CAGR through 2030 as palatable chewables and flavored suspensions win owner acceptance for chronic conditions. Zoetis’s launch of Apoquel Chewable showcases this direction, linking convenience with compliance and boosting repeat purchases. Sustained-release oral technologies further reduce dosing frequency, promoting adherence and justifying premium pricing in the Australia veterinary healthcare market.
Topical and transdermal innovations add choice for ectoparasite control, and implantable devices appear for hormonal modulation in reproduction management. As the therapeutic arsenal diversifies, clinics can tailor regimens, elevating perceived value and revenue across the Australia veterinary healthcare market.
Note: Segment shares of all individual segments available upon report purchase
Get Detailed Market Forecasts at the Most Granular Levels
Download PDF
By End User: Hospitals Lead, Point-of-Care Testing Emerges
Hospitals and clinics retained 53.76% share in 2024 as the primary touchpoint for surgery, imaging, and inpatient care. Consolidators like VetPartners leverage scale to standardize quality and negotiate supplier terms. Point-of-care settings, though smaller, rise at an 8.43% CAGR by decentralizing diagnostics into general practice and farm environments. Clinicians armed with portable hematology, ultrasound, and molecular kits deliver rapid answers, enabling same-visit treatments and reducing referral leakage. Retail pharmacy and e-commerce channels supplement product access but prescription control remains within veterinary oversight, preserving revenue pillars for brick-and-mortar clinics in the Australia veterinary healthcare market.
Mobile and telehealth models target workforce shortages in the bush, adding service capacity without permanent facilities. As these hybrid approaches mature, end-user segmentation will reflect a continuum from large hospitals to virtual platforms, broadening reach of the Australia veterinary healthcare market.
Competitive Landscape
The Australia veterinary healthcare market reports moderate consolidation as private equity inflows chase scale economies and brand leverage. EQT’s acquisition of VetPartners in January 2025 created a 267-clinic network employing more than 1,300 veterinarians, intensifying bargaining power with suppliers and accelerating protocol standardization. Greencross, valued at USD 3.75 billion, evaluates an ASX relisting to unlock capital for digital initiatives and clinic refurbishments. U.K.-based CVS Group invested USD 82.5 million to secure 28 Australian sites, signaling continued cross-border interest in local assets.
Pharmaceutical manufacturers expand production footprints to secure supply sovereignty. Zoetis purchased a 21-acre Melbourne plant in August 2024, doubling its vaccine output and aligning with government calls for domestic capability. Technology vendors differentiate practices: 30% of clinicians now rely on AI diagnostics to shorten wait times and elevate accuracy, appealing to quality-conscious owners. Practice management software providers integrate compliance modules that ease APVMA documentation, lowering administrative burdens and sharpening competitive positioning.
White-space remains in remote service delivery. Telehealth triage, mobile surgical units, and subscription wellness plans aim to bridge clinician gaps in the outback while generating recurring revenue. Workforce initiatives focus on retention bonuses and mental health support to curb attrition. As consolidation continues, the Australia veterinary healthcare market will likely reach an equilibrium where a handful of corporate groups coexist with high-touch independents that command localized loyalty.
Australia Veterinary Healthcare Industry Leaders
-
Zoetis Inc
-
Vetoquinol SA
-
Merck Co. Inc.
-
Elanco Animal Health
-
Boehringer Ingelheim Animal Health
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- January 2025: EQT agreed to acquire VetPartners, Australia’s largest veterinary services network with 267 clinics and more than 1,300 veterinarians, signaling deeper private-equity commitment to the country’s animal-health services sector.
- January 2025: The Australian Pesticides and Veterinary Medicines Authority began a simultaneous approval pathway with U.K. regulators, cutting registration times for new veterinary drugs and devices sold in Australia.
- November 2024: The Federal Government allocated an additional USD 95 million to bolster avian influenza preparedness, expanding Australia’s total biosecurity investment beyond USD 1 billion and driving demand for diagnostics and vaccines.
- August 2024: Zoetis purchased a 21-acre manufacturing site in Melbourne, doubling domestic vaccine production capacity and strengthening Australia’s supply resilience for livestock and companion-animal biologics.
- May 2024: The New South Wales Government produced the world’s first mRNA vaccine for border disease virus, establishing local capability for rapid response to emerging animal diseases.
Australia Veterinary Healthcare Market Report Scope
As per the scope of this report, the Australia veterinary healthcare market is growing, and it comprises therapeutic and diagnostic products and solutions for companion and farm animals. Companion animals can be tamed or adopted for companionship or as house/office guards, and farm animals are raised for meat and milk-related products. Companion animals include canines, felines, and equines. Farm animals include bovine, poultry, and porcine. The Australia Veterinary Healthcare Market is segmented on The Basis of Product (Therapeutics And Diagnostics) and Animal Type (Dogs And Cats, Horses, Ruminants, Swine, Poultry, and Other Animals). The report offers the value (in USD million) for the above segments.
By Product
| Therapeutics | Vaccines |
| Parasiticides | |
| Anti-Infectives | |
| Medical Feed Additives | |
| Other Therapeutics | |
| Diagnostics | Immunodiagnostic Tests |
| Molecular Diagnostics | |
| Diagnostic Imaging | |
| Clinical Chemistry | |
| Point-Of-Care Testing Devices |
By Animal Type
| Other Diagnostics |
| Dogs & Cats |
| Horses |
| Ruminants |
| Swine |
| Poultry |
| Other Animal Types |
By Route Of Administration
| Oral |
| Parenteral |
| Topical |
| Other Route of Administrations |
By End User
| Veterinary Hospitals & Clinics |
| Reference Laboratories |
| Point-Of-Care / In-House Testing Settings |
| Academic & Research Institutes |
| By Product | Therapeutics | Vaccines |
| Parasiticides | ||
| Anti-Infectives | ||
| Medical Feed Additives | ||
| Other Therapeutics | ||
| Diagnostics | Immunodiagnostic Tests | |
| Molecular Diagnostics | ||
| Diagnostic Imaging | ||
| Clinical Chemistry | ||
| Point-Of-Care Testing Devices | ||
| By Animal Type | Other Diagnostics | |
| Dogs & Cats | ||
| Horses | ||
| Ruminants | ||
| Swine | ||
| Poultry | ||
| Other Animal Types | ||
| By Route Of Administration | Oral | |
| Parenteral | ||
| Topical | ||
| Other Route of Administrations | ||
| By End User | Veterinary Hospitals & Clinics | |
| Reference Laboratories | ||
| Point-Of-Care / In-House Testing Settings | ||
| Academic & Research Institutes | ||
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
What is the current value of the Australia veterinary healthcare market?
The market is valued at USD 1.09 billion in 2025 with a forecast to reach USD 1.55 billion by 2030.
What CAGR is expected through 2030?
A compound annual growth rate of 7.84% is projected for 2025-2030.
Which product category leads revenue?
Therapeutics lead with 61.34% share in 2024, driven by vaccines and parasiticides.
Which segment is growing fastest?
Diagnostics show the highest growth at a 7.45% CAGR due to preventive care focus and AI adoption.
How significant is poultry in future growth?
Poultry is the fastest-expanding animal segment at an 8.45% CAGR because of export-related health requirements.
What challenges limit expansion?
High service costs and an enduring veterinary workforce shortage remain the primary hurdles.
Page last updated on:
